These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28689434)

  • 1. Role of genetic testing in patients undergoing percutaneous coronary intervention.
    Moon JY; Franchi F; Rollini F; Rivas Rios JR; Kureti M; Cavallari LH; Angiolillo DJ
    Expert Rev Clin Pharmacol; 2018 Feb; 11(2):151-164. PubMed ID: 28689434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.
    Galli M; Franchi F; Rollini F; Cavallari LH; Capodanno D; Crea F; Angiolillo DJ
    Expert Rev Clin Pharmacol; 2021 Aug; 14(8):963-978. PubMed ID: 33993817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
    Johnson SG; Gruntowicz D; Chua T; Morlock RJ
    J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial.
    Sardella G; Calcagno S; Mancone M; Lucisano L; Pennacchi M; Stio RE; Placentino F; Di Roma A; Cavallo E; Palmirotta R; Guadagni F; Fedele F
    Int J Cardiol; 2015 Sep; 194():60-2. PubMed ID: 26011265
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
    Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
    Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
    Khan JN; Greenwood JP; Nazir SA; Lai FY; Dalby M; Curzen N; Hetherington S; Kelly DJ; Blackman D; Peebles C; Wong J; Flather M; Swanton H; Gershlick AH; McCann GP
    J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
    Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
    BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
    Lee JH; Ahn SG; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J; Kim J; Choi E; Yoo SY; Hung OY; Samady H
    Platelets; 2016 Jun; 27(4):301-7. PubMed ID: 26556524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
    Floyd CN; Passacquale G; Ferro A
    Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center.
    Dalal JJ; Digrajkar A; Gandhi A
    Indian Heart J; 2016; 68(5):624-631. PubMed ID: 27773400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of P2Y
    Thomas CD; Williams AK; Lee CR; Cavallari LH
    Pharmacotherapy; 2023 Feb; 43(2):158-175. PubMed ID: 36588476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
    Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
    Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
    Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
    J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
    Roffman DS
    J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.